ASH 2023 | Nelarabine, PEG-asparaginase and venetoclax added to HCVAD in T-ALL/T-LBL

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the incorporation of novel agents such as nelarabine and PEG-asparaginase into front-line treatment for T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/T-LBL). Although agents such as nelarabine have been previously studied and assessed in pediatric patients, data in adult patients is scarce. Dr Ravandi highlights data from an ongoing Phase II study of 133 adult patients treated with a regimen of nelarabine, PEG-asparaginase and venetoclax in combination with HCVAD chemotherapy, prior to allogeneic stem cell transplantation (alloSCT). The results reported at the ASH 2023 meeting indicated that incorporating these agents to the HCVAD regimen leads to promising long-term survival in adult patients with T-ALL/LBL, however larger studies with a longer follow-up are necessary to understand the full benefit of this regimen. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.